Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Neoplasm Metastasis × palbociclib × Dermatologic × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 18 Tumor-Agnostic 2 Gynecologic 2 Sarcoma 1 Plasma cell 1 Other hematologic neoplasm 1 Myeloid 1 Lymphoid 1 Genitourinary 1 Gastrointestinal 1 Dermatologic 1 Classical hematology 1

Conditions

Melanoma 6 Neoplasms 2 Testicular Neoplasms 1 Teratoma 1 Rectal Neoplasms 1 Pancreatic Neoplasms 1 Neoplasm Metastasis 1 Colonic Neoplasms 1 Breast Neoplasms, Male 1 Breast Neoplasms 1

Interventions

pembrolizumab 30 Cyclophosphamide 22 Nivolumab 21 aldesleukin 19 Ipilimumab 19 Interleukin-2 15 fludarabine 14 Specimen Handling 11 fludarabine phosphate 10 Dacarbazine 10 Radiosurgery 9 Magnetic Resonance Spectroscopy 9 Biopsy 9 Temozolomide 8 dabrafenib 5 cemiplimab 5 Vemurafenib 5 Radiotherapy 5 trametinib 4 sargramostim 4 binimetinib 4 avelumab 4 Paclitaxel 4 Cisplatin 4 Bevacizumab 4 lenvatinib 3 encorafenib 3 durvalumab 3 Pemetrexed 3 Lenalidomide 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04720768 2024-01-05

CELEBRATE

Peter MacCallum Cancer Centre, Australia

Phase 1/2 Unknown

Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon ⚡